trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['dance', 't-dxd', 'bcsm', 'tnbc']
dynamic her2-low status in tnbc *increased likelihood of her2-low with more biopsies
*greatest discordance between early and metastatic *consider repeat biopsies if feasible &amp; safe to identify patients who may benefit from t-dxd yael bar of #asco23 #bcsm 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.